Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line
immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data …

Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …

Diagnosis should be based on a surgical specimen/excisional lymph node (LN) biopsy.
Core biopsies should only be carried out in patients without easily accessible LNs (eg …

Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and
clinical behavior. Patients typically present with persistent painless lymphadenopathy, but …

We assessed the incidence, prognostic features, and outcomes associated with
transformation of follicular lymphoma (FL) among 2652 evaluable patients prospectively …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the
Western hemisphere. After decades of stagnation, the natural history of FL appears to have …

Disease overview Follicular lymphoma is generally an indolent B cell lymphoproliferative
disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by …